Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease.
Identifieur interne : 000459 ( Ncbi/Curation ); précédent : 000458; suivant : 000460Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease.
Auteurs : Ya Feng [République populaire de Chine] ; Te Liu [République populaire de Chine] ; Xin Li [États-Unis] ; Ye Liu [République populaire de Chine] ; Xiao Zhu [République populaire de Chine] ; Joseph Jankovic [États-Unis] ; Tian Pan [États-Unis] ; Yun Wu [République populaire de Chine]Source :
- Neuroscience letters ; 2014.
English descriptors
- KwdEn :
- Cell Line, Humans, Hypoxia-Inducible Factor 1, alpha Subunit (biosynthesis), Intracellular Signaling Peptides and Proteins (pharmacology), MPTP Poisoning (chemically induced), MPTP Poisoning (pathology), Neuropeptides (pharmacology), Neuroprotective Agents (pharmacology), Orexins, Suppression, Genetic (drug effects), Vascular Endothelial Growth Factor A (metabolism).
- MESH :
- chemical , biosynthesis : Hypoxia-Inducible Factor 1, alpha Subunit.
- chemical , metabolism : Vascular Endothelial Growth Factor A.
- chemical , pharmacology : Intracellular Signaling Peptides and Proteins, Neuropeptides, Neuroprotective Agents.
- chemically induced : MPTP Poisoning.
- drug effects : Suppression, Genetic.
- pathology : MPTP Poisoning.
- Cell Line, Humans, Orexins.
Abstract
Orexin-A, a neuropeptide secreted by hypothalamic neurons, may be neuroprotective in many neurological conditions such as cerebral ischaemia. One mechanism postulated to be involved in the neuroprotection by Orexin-A is the induction of hypoxia inducible factor 1 alpha (HIF-1α). Parkinson's disease (PD) is a progressive neurodegenerative disorder and mitochondrial dysfunction has been demonstrated to play a role in its pathogenesis. Mitochondrial dysfunction may cause reduction of O2 consumption and subsequently activate prolyl hydroxylase, which leads to decreased level of HIF-1α. In this study, we used MPP(+)-treated SH-SY5Y cells as an in vitro cellular model of PD to test the role of Orexin-A as an inducer of HIF-1α. Our results showed that Orexin-A not only induced HIF-1α but also activated downstream targets of HIF-1α, such as vascular endothelial growth factor and erythropoietin. Thus, Orexin-A treatment attenuated MPP(+)-induced cell injury and this effect was blocked when HIF-1α was suppressed. Hence, we conclude that induction of HIF-1α is one of the mechanisms involved in the neuroprotection by Orexin-A.
DOI: 10.1016/j.neulet.2014.07.014
PubMed: 25038418
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000026
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000026
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000029
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000459
Links to Exploration step
pubmed:25038418Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease.</title><author><name sortKey="Feng, Ya" sort="Feng, Ya" uniqKey="Feng Y" first="Ya" last="Feng">Ya Feng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Te" sort="Liu, Te" uniqKey="Liu T" first="Te" last="Liu">Te Liu</name><affiliation wicri:level="1"><nlm:affiliation>Shanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200031</wicri:regionArea><wicri:noRegion>Shanghai 200031</wicri:noRegion></affiliation></author><author><name sortKey="Li, Xin Qun" sort="Li, Xin Qun" uniqKey="Li X" first="Xin" last="Li">Xin Li</name><affiliation wicri:level="2"><nlm:affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Liu, Ye" sort="Liu, Ye" uniqKey="Liu Y" first="Ye" last="Liu">Ye Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author><author><name sortKey="Zhu, Xiao Ying" sort="Zhu, Xiao Ying" uniqKey="Zhu X" first="Xiao" last="Zhu">Xiao Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Pan, Tian Hong" sort="Pan, Tian Hong" uniqKey="Pan T" first="Tian" last="Pan">Tian Pan</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: Tpan1@mdanderson.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Wu, Yun Cheng" sort="Wu, Yun Cheng" uniqKey="Wu Y" first="Yun" last="Wu">Yun Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China. Electronic address: yunchw@medmail.com.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25038418</idno><idno type="pmid">25038418</idno><idno type="doi">10.1016/j.neulet.2014.07.014</idno><idno type="wicri:Area/PubMed/Corpus">000026</idno><idno type="wicri:Area/PubMed/Curation">000026</idno><idno type="wicri:Area/PubMed/Checkpoint">000029</idno><idno type="wicri:Area/Ncbi/Merge">000459</idno><idno type="wicri:Area/Ncbi/Curation">000459</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease.</title><author><name sortKey="Feng, Ya" sort="Feng, Ya" uniqKey="Feng Y" first="Ya" last="Feng">Ya Feng</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Te" sort="Liu, Te" uniqKey="Liu T" first="Te" last="Liu">Te Liu</name><affiliation wicri:level="1"><nlm:affiliation>Shanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200031</wicri:regionArea><wicri:noRegion>Shanghai 200031</wicri:noRegion></affiliation></author><author><name sortKey="Li, Xin Qun" sort="Li, Xin Qun" uniqKey="Li X" first="Xin" last="Li">Xin Li</name><affiliation wicri:level="2"><nlm:affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Liu, Ye" sort="Liu, Ye" uniqKey="Liu Y" first="Ye" last="Liu">Ye Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author><author><name sortKey="Zhu, Xiao Ying" sort="Zhu, Xiao Ying" uniqKey="Zhu X" first="Xiao" last="Zhu">Xiao Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Pan, Tian Hong" sort="Pan, Tian Hong" uniqKey="Pan T" first="Tian" last="Pan">Tian Pan</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: Tpan1@mdanderson.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Wu, Yun Cheng" sort="Wu, Yun Cheng" uniqKey="Wu Y" first="Yun" last="Wu">Yun Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China. Electronic address: yunchw@medmail.com.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080</wicri:regionArea><wicri:noRegion>Shanghai 200080</wicri:noRegion></affiliation></author></analytic><series><title level="j">Neuroscience letters</title><idno type="e-ISSN">1872-7972</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell Line</term><term>Humans</term><term>Hypoxia-Inducible Factor 1, alpha Subunit (biosynthesis)</term><term>Intracellular Signaling Peptides and Proteins (pharmacology)</term><term>MPTP Poisoning (chemically induced)</term><term>MPTP Poisoning (pathology)</term><term>Neuropeptides (pharmacology)</term><term>Neuroprotective Agents (pharmacology)</term><term>Orexins</term><term>Suppression, Genetic (drug effects)</term><term>Vascular Endothelial Growth Factor A (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Hypoxia-Inducible Factor 1, alpha Subunit</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Intracellular Signaling Peptides and Proteins</term><term>Neuropeptides</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Suppression, Genetic</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Humans</term><term>Orexins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Orexin-A, a neuropeptide secreted by hypothalamic neurons, may be neuroprotective in many neurological conditions such as cerebral ischaemia. One mechanism postulated to be involved in the neuroprotection by Orexin-A is the induction of hypoxia inducible factor 1 alpha (HIF-1α). Parkinson's disease (PD) is a progressive neurodegenerative disorder and mitochondrial dysfunction has been demonstrated to play a role in its pathogenesis. Mitochondrial dysfunction may cause reduction of O2 consumption and subsequently activate prolyl hydroxylase, which leads to decreased level of HIF-1α. In this study, we used MPP(+)-treated SH-SY5Y cells as an in vitro cellular model of PD to test the role of Orexin-A as an inducer of HIF-1α. Our results showed that Orexin-A not only induced HIF-1α but also activated downstream targets of HIF-1α, such as vascular endothelial growth factor and erythropoietin. Thus, Orexin-A treatment attenuated MPP(+)-induced cell injury and this effect was blocked when HIF-1α was suppressed. Hence, we conclude that induction of HIF-1α is one of the mechanisms involved in the neuroprotection by Orexin-A.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000459 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000459 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:25038418
|texte= Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25038418" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |